ACON
Aclarion, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
0.00
P/S
24.01
EV/EBITDA
1689966.31
DCF Value
$22,584,539.07
FCF Yield
-393944079.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
-291.3%
Operating Margin
-9312.5%
Net Margin
-9551.9%
ROE
-0.0%
ROA
-0.0%
ROIC
-0.0%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $18.5K | $-1.9M | $-2.21 |
| FY 2025 | $75.7K | $-7.2M | $-13.61 |
| Q3 2025 | $18.9K | $-1.7M | $-2.93 |
| Q2 2025 | $19.3K | $-1.6M | $-2.75 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
1.14
Aclarion, Inc., a healthcare technology company, develops software application for magnetic resonance spectroscopy (MRS) in the United States. It offers NOCISCAN-LS Post-Processor suite comprising NOCICALC-LS that receives and processes the acquired disc MRS data to calculate levels of degenerative pain biomarkers; and NOCIGRAM-LS, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was founded in 2008 and is based in San Mateo, California.